Reuters, July 27, 2022 Pfizer Inc (PFE.N) and its German partner BioNTech SE (22UAy.DE) said on Wednesday they had started a mid-stage study of a modified COVID-19 vaccine which targets both the original as well as the BA.2 Omicron subvariant. Pfizer said the vaccine …
U.S. orders 3.2 million doses of Novavax COVID vaccine
Staff Writer, Reuters, July 11, 2022 The U.S. government will get 3.2 million doses of COVID-19 vaccine developed by Novavax Inc (NVAX.O) once the shot has been authorized by the regulators, the Department of Health and Human Services (HHS) and the company …
U.S. FDA sets June meeting dates for Moderna, Pfizer small children COVID-19 vaccines
Staff Writer, Reuters, May 23, 2022 The U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc’s emergency authorization request for its COVID-19 vaccine for children aged 6 months to 5 years and …
COVID vaccine makers shift focus to boosters
Michael Erman and Manas Mishra, Reuters, May 9, 2022 COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months. …
Pfizer says COVID treatment Paxlovid fails to prevent infection of household members
Deena Beasley, Reuters, April 29, 2022 Pfizer Inc (PFE.N) on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone infected with the virus. The trial enrolled …